Cargando…
Fabry disease: Mechanism and therapeutics strategies
Fabry disease is a monogenic disease characterized by a deficiency or loss of the α-galactosidase A (GLA). The resulting impairment in lysosomal GLA enzymatic activity leads to the pathogenic accumulation of enzymatic substrate and, consequently, the progressive appearance of clinical symptoms in ta...
Autores principales: | Li, Xi, Ren, Xiangyi, Zhang, Yabing, Ding, Lin, Huo, Minfeng, Li, Qian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643830/ https://www.ncbi.nlm.nih.gov/pubmed/36386210 http://dx.doi.org/10.3389/fphar.2022.1025740 |
Ejemplares similares
-
Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review
por: Palaiodimou, Lina, et al.
Publicado: (2023) -
Nanozymes-recent development and biomedical applications
por: Ren, Xiangyi, et al.
Publicado: (2022) -
Immunometabolism changes in fibrosis: from mechanisms to therapeutic strategies
por: Feng, Lixiang, et al.
Publicado: (2023) -
Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
por: Fu, Yajie, et al.
Publicado: (2022) -
Dysfunctions, Molecular Mechanisms, and Therapeutic Strategies of Regulatory T Cells in Rheumatoid Arthritis
por: Li, Xiaoya, et al.
Publicado: (2021)